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Abstract
Obesity, being an epidemy these days, is the trigger of metabolic disturbances 
such as cardiovascular disease, type 2 diabetes, and insulin resistance. Defined as an 
increase in fat storage, adipose tissue has been put under the spotlight as the culprit 
of these conditions, as it is composed not only by adipocytes but of any immune 
system cell and a singular extracellular matrix. Its behavior under acute and chronic 
hypercaloric states is quite different; persistent hypertrophy in the latter creates 
hypoxia, resulting in the release of reactive oxygen species and proinflammatory 
cytokines that impact on the immune response type of the resident leucocytes, 
mainly macrophages. Hypertrophy over hyperplasia, adipose tissue macrophages-
M1 phenotype polarization, and the adipokines/myokines profile are thought to 
be regulated by foreign microRNAs, delivered from surrounding or distant cells 
by exosomes through the bloodstream. In this chapter, we focus on adipose tissue 
immunometabolism and how obesity causes the chronic inflammatory state, and, 
subsequently, this stablishes a pathologic adiposity, characterized by dyslipidemia 
and insulin resistance (IR).
Keywords: obesity, adipose tissue, adipose tissue macrophages-M1 phenotype, 
exosomes, microRNAs, insulin resistance, pathologic adiposity
1. Introduction
Novel findings on the immune-regulatory processes and metabolic mechanisms 
may open new avenues in the complex diseases as well as obesity; research on 
basic and clinical advances in immunometabolism has evolved rapidly during the 
past years, and the emergence of new tools for the detection and characterization 
of regulation of inflammation in systemic inflammatory diseases with metabolic 
comorbidity may play an imperative role.
Interplay in regulation of inflammation and metabolic risk factors are a complex 
cluster. The inflammatory condition associated with adipose tissue represents a 
triggering factor in the etiology of the obesity pathological-mechanism and mainly 
contributes to the related disease outcomes.
The purpose of this chapter is to address recent findings in metabolic, molecular 
biology, function, and pathology of the immune response to inflammation on the 
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role of the immunometabolism in obesity. That containing significant new findings 
in the field, presenting the state of the art findings, will offer the new insights into 
interplay in the regulation of inflammation, especially in the tools of the comorbid-
ity, in order to know their mechanisms by metabolic and immune response that 
cause disease.
2. Healthy adipose tissue
2.1 Morphology and cellular biology
Adipose tissue (AT) is a type of specialized connective tissue, and as such, it 
consists of two main components: a cellular population and a specialized extracel-
lular matrix (ECM) [1].
The cellular population is integrated not only by adipocytes (the main cell type, 
by which receives its name) but also by preadipocytes, mesenchymal stem cells 
(MSCs), fibroblasts, endothelial and smooth muscle cells of blood vessels and any 
immune system cell, and adipose tissue macrophages (ATMs) with relevance [2, 3].
Its ECM, as any other, is composed of a wide type of collagens (fibrillar (I and 
III) and nonfibrillar (IV, VI, and VIII)), laminins, fibronectin, and proteoglycans; 
especially the external membrane contains a large complex of collagen IV and 
VIII as well as heparan sulfate proteoglycans and laminins [4]. AT ECM possesses 
the highest collagen VI concentration compared to any other body tissue [5, 6]. 
Altogether, the ECM and the non-adipocyte cellular population receive the name of 
stromal-vascular fraction (SVF) [7].
2.1.1 Classification
Histologically, AT is classified according to adipocyte microscopic characteristics 
as white (WAT), brown (BAT), and beige. White adipocytes are big oval cells with 
a single lipid droplet that fills the whole cytoplasm, displacing the nucleus and 
other organelles through periphery; its main function is the storage of energy in 
the form of triglycerides (TG) and lipolysis. Brown adipocytes are oval cells with 
multilocular lipid droplets uniformly distributed over the cytoplasm and have a 
high number of mitochondria, each one with several cristae expressing uncoupling 
protein 1 (UCP-1), characteristics that reflect an important thermogenic property. 
Beige adipocytes are cells with brown phenotype within WAT, that is why they are 
also called brite (brown-in-white) adipocytes; under basal conditions they express 
low quantity of UCP-1 but can overexpress it upon β-adrenergic simulation and 
thus acquire thermogenic function [8–10].
Moreover, adipose tissue has an important endocrine function, as it is capable to 
secrete own specific hormones called adipokines [11].
2.1.2 Fat depots
In humans WAT constitutes close to 5–10% of total human body weight and is 
located in two main compartments: intra-abdominal, named visceral AT (VAT), 
and subcutaneous AT (SCAT), also called hypodermis. VAT coats internal organs 
and protects them from mechanical friction and damage and can be divided into 
omental, mesenteric, retroperitoneal, gonadal and pericardial; SCAT is designated 
according to its superficial or deep situation regarding to the fascia superficialis as 
lamellar or areolar [12]. Moreover, abdominal and gluteofemoral regions are more 
relevant regarding of functional properties [13, 14].
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It is remarkable to note that gender-related differences in distribution and 
quantity exist. While women have more SCAT (especially in gluteofemoral and 
peripheral regions), men have more VAT because SCAT has higher levels of estrogen 
and progesterone receptors, while VAT has more androgen receptors [15, 16].
In rodents, the main SCAT pads are anterior, from the neck to the axillae running 
through the interscapular area, and posterior, from the dorsolumbar to the gluteal 
region running through the inguinal region. Also, the striated muscle called pan-
niculus carnosus clearly separates two layers of WAT depots: one directly underlying 
the reticular dermis and SCAT as such [17]; the former compartment is designated 
as dermal WAT (DWAT), composed primarily by intradermal adipocytes. These 
two terms were proposed as a redefinition of the nomenclature of skin-associated 
adipocytes, as it more accurately reflects their immediate developmental origin and 
anatomical location; humans, although not having a panniculus carnosus, possess 
functional and morphological distinctions between DWAT and SCAT [18, 19].
Differentiation, lipolytic and endocrine activity, and leucocyte population differ 
between VAT and SCAT, conferring them distinct metabolic properties and, in case 
of VAT, attribution of metabolic disturbances like dyslipidemia, glucose intolerance, 
and insulin resistance (IR) [20].
2.2 Immunometabolism
As an interdisciplinary field, immunometabolism emerged from discoveries 
of interdependent functions and mechanisms between the immune system and 
parenchymal cells of metabolic organs, which confer adaptive processes in homeo-
stasis or disease at cellular, tissue, and systemic level [21, 22]. AT is the most studied 
in this field.
2.2.1 Immune response
Immune system has an important role on the control of AT homeostatic state, 
where its main functions are keeping an anti-inflammatory environment and 
remodeling of the extracellular matrix [8].
Under physiologic state, AT leucocyte population is integrated by eosinophils, 
mast cells, group 2 innate lymphoid cells (ILC2), invariant natural killer T cells 
(iNKT), regulatory T lymphocytes (Treg), and, of particular interest, adipose 
tissue macrophages (ATMs). It is proposed that these immune cells contribute to 
the maintenance of AT integrity through secretion of cytokines such as IL-4, IL-5, 
IL-13, and IL-10 (a Th2-type immune response) and that under hypercaloric state, 
macrophage accumulation may be a protective mechanism of the body to cope 
metabolic disturbances [23].
IL-33 produced by endothelial stromal cells has a key role in homeostatic main-
tenance and function of ECM. It is ligand of ST2 receptor, which is expressed in 
mast cells, Treg, eosinophils, ILC2s, and iNKT cells, practically the whole resident 
leucocyte population [24, 25].
In vitro and in vivo studies have demonstrated important effects of IL-33: pro-
duction of IL-5 and IL-13 by Th2 lymphocytes and macrophages, eosinophil IL-4 
production and survival, as well as ILC2s survival and expansion, the latter similar 
for Tregs [26]. iNKT cells express the transcriptional factor E4BP4; in adipose tissue 
produce anti-inflammatory cytokines, such as IL-2, IL-4, and IL-10; and participate 
in control of the homeostasis of Treg cells and macrophages in this tissue [27].
IL-25 promotes lipid metabolism and energy production, improves mitochon-
drial respiratory capacity, and alleviates lipid accumulation in the liver and AT via 
M2 macrophages and its interaction with adipocytes.
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As we can observe, AT leucocytes produce the Th2-type cytokines, profile that 
favors the maintenance of ATMs in an anti-inflammatory M2 phenotype, known 
for the expression of arginase-1 (Arg-1, which inhibits iNOS activity) and produc-
tion of IL-10 and IL-1Ra. ATMs also play an important lipid “buffering” activity, 
as they engulf free fatty acids (FFA) coming from adipocytes that have surpassed 
their lipid storage capacity and unchain lipolysis. Moreover, ATMs engulf death 
adipocytes that have reached a critical death size (CDS) [28] by a process named 
efferocytosis [29].
Thus, ATM is the fundamental leucocyte for correct AT functionality, as it 
engulfs apoptotic cell debris, and, FFA released whether by lipolysis or adipocyte 
death, promotes ECM reconstruction [30] and provides ECM components as 
scaffolds for its remodeling in the same way as under wound healing process; all 
these mechanisms promote adipogenesis and hyperplastic AT expansion. It is worth 
noting that these beneficial functions take place only under an anti-inflammatory 
M2 phenotype (Figure 1).
2.2.2 ECM remodeling
The ECM of any specialized connective tissue is essential not only for mechanic 
and structural sustain but also for providing a network that permits inter- and 
extracellular communication that enables proper growth and differentiation [1]. 
AT ECM is no exception, and its remodeling is regulated by resident leucocytes and 
own adipocytes.
WAT can undergo remodeling in response to changes in energy balance, like 
ECM degradation by members of the matrix metalloproteinase (MMP) family dur-
ing adipocyte enlargement (hypertrophy) and allowing expansion by adipogenesis, 
under a positive energy balance [31, 32]; on the other hand, MMP activity counter-
regulation is mediated by their tissue inhibitors (TIMPs). The balance between 
MMPs and TIMPs is critical for ECM integrity and function, and alterations in this 
proteolysis balance may contribute to many pathological states [33].
Secreted protein, acidic, and rich in cysteine complex (SPARC)/osteonectin 
and its C and N isoforms contribute to AT ECM remodeling; they modulate 
cell-ECM contact, cell-cell interaction, ECM deposition, and adipose stem cells 
(ASCs) migration and posterior incorporation into expanding neovasculature 
Figure 1. 
Adipose tissue homeostatic immunometabolism.
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accompanying WAT growth [34]. A study showed that serum concentrations 
of SPARC and MMP-2 after bariatric surgery decreased, SMAC correlated with 
HOMA-IR, and MMP-9 inversely correlated with serum adiponectin levels [35].
Regarding vasculature, AT ECM remodeling is influenced by a variety of 
angiogenic molecules, and it is triggered by transient hypoxia as a result of enlarged 
adipocytes under a positive energy balance. Hypoxia stimulates the production of 
angiogenic factors to compensate low perfusion rate; vascular endothelial growth 
factor (VEGF) is known as a master regulator of angiogenesis and plays crucial 
roles in the neovascular development of AT with obesity [36]. Hypoxia-inducible 
factor-1α (HIF-1α) binds to the proximal hypoxia response element in the VEGF 
gene promoter [37]; nevertheless, it also has a role in regulation of ECM remodel-
ing, as overexpression of a constitutively active form of HIF-1α in adipose tissue 
forced the expression of pro-fibrotic genes, including Col I and III, elastin, lysyl 
oxidase, and Timp1 [38].
This shows that detrimental ECM component deposition occurs under 
chronic hypoxic conditions. Transforming growth factor beta (TGFβ) and 
tumor necrosis factor-α (TNF-α) are released under acute hypoxia state and act 
as proangiogenic factors [39, 40], and the latter activates expression of preadi-
pocyte genes in 3T3-L1 adipocytes [41]. This is in contrast to the belief that AT 
inflammation exerts a fundamentally negative impact on metabolism, postulat-
ing the concept “healthy inflammation” under overnutrition, requiring an acute 
local inflammation in order to prevent lipotoxicity and ectopic lipid accumula-
tion; in this regard, a report showed the analysis of three animal models with 
constitutive or inducible expression of anti-inflammatory factors and revealed 
their inability to expand AT, leading to ectopic lipid deposition and deteriorated 
metabolic profile [42].
Platelet-derived growing factor B (PDGF-B), usually produced by endothelial 
cells, activates an intracellular signaling cascade binding to its receptor (PDGFRβ) 
and promotes pericyte detachment and migration around new-forming vessels for 
maturation, playing key roles in vascular development and wound healing in adults 
via angiogenic actions [43]. Surprisingly, Onogi Y. and colleagues found that M1 
macrophages were a major type of cells expressing PDGF-B in obese adipose tissue 
and correlated with elevated pericyte detachment in a dose-dependent manner; in 
contrast, inducible knockout pdgfrb mice presented reduced M1 macrophages and 
CLS formation but increased M2 macrophages. Additionally, they were protected 
from body weight gain, accumulation of SCAT, VAT, and ectopic fat in muscle and 
liver and showed improved whole-body glucose metabolism under high-fat diet 
(HFD) condition. The expression of hypoxic and proinflammatory factors (Hif1a, 
Emr1, Itgax, Mrc1, Tnfa, and Ccl2) was significantly increased by HFD feeding mice, 
whereas the increasing effects were attenuated in HFD-fed PDGFRB-KO mice [44]. 
Also, increased adipogenic capacity of PDGFRβ+ precursors through PPARG overex-
pression in pericytes resulted in healthy VAT expansion in obesity and adiponectin-
dependent improvements in glucose homeostasis, in contrast with knockout PPARG 
counterparts; moreover, the ability of the thiazolidinedione (TZD) class of antidia-
betic drugs to promote healthy visceral WAT remodeling is dependent on mural cell 
PPARG [45].
An experimental in vivo study consisting of brown adipogenesis by 
β3-adrenergic receptor (ADRB3) activation caused crown-like structures (CLSs) 
formation: white adipocyte death recruited M2-polarized macrophages with high 
expression of osteopontin (OPN), which in turn attracted a subpopulation of 
PDGFRα+ CD44+ (OPN receptor) progenitors that underwent adipogenesis, in 
contrast with knockout OPN [46]. It is important to highlight that recruited M2 
macrophages also showed upregulation of Arg1 and Il10 without significant changes 
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in proinflammatory markers, indicating that ADRB3-mediated adipogenesis 
involves recruitment of macrophages that mediate non-inflammatory tissue repair 
[47]. Another study combining experiments in mouse models and human condi-
tions reported that PDGFRα + CD9high cells originate pro-fibrotic cells, while their 
CD9low counterparts harbored pro-adipogenic potential; frequency of PDGFRα + 
CD9high in omental WAT (oWAT) correlated not only to oWAT fibrosis level but also 
to the severity of insulin resistance and T2D [48].
Adipokines can also help regulate angiogenesis, a sustained and progressive 
increase in leptin resulting from hypoxic conditions could induce VEGF and 
receptor (VEGFR2) expression, activate sirtuin 1 (SIRT1), and subsequent HIF-2α 
stabilization promoting its activity [49].
2.2.3 Glucose and lipid metabolism
A steady and continuous energy supply is necessary for all cells’ survival; the 
production of the principal high-energy molecule, the adenosine triphosphate 
(ATP), is primarily obtained by the metabolism of such molecules as glucose and 
fatty acids. In the case of carbohydrates, these are the main source of energy in 
almost every living organism, from archaea to humans. It is not only the supply of 
these molecules, but also the intricate mechanism of regulation of pathways that 
control the consumption and storage of these biomolecules.
For example, after a meal, or what is called a post absorptive state, there is an 
increment of plasmatic glucose concentration which results in the secretion of 
hormones such as insulin by the pancreas; this contributes to the regulation of 
glucose metabolism as well, and the physiological response varies on every tissue, as 
can been seen in muscle and liver, where insulin favors glycolysis and glycogenesis. 
Nevertheless, this hormone not only alters the carbohydrates metabolism, but also 
promotes cholesterol synthesis and lipogenesis (or TG synthesis) in hepatic and 
adipose tissues [50].
In the case of glycolysis, it represents the central path for glucose metabolism 
and provides multiple intermediate products. On aerobic conditions, it starts in the 
cytoplasm of the cell, with glucose as a substrate, which is partially oxidized by 10 
enzymatic reactions, obtaining two pyruvate molecules, reducing equivalents such 
as NADH (nicotinamide adenine dinucleotide in reduced form) and a net produc-
tion of 2 ATPs for each glucose [51].
Afterward, the pyruvate molecules will be transformed into acetyl-CoA and 
transported into the mitochondria to continue their oxidation in the tricarboxylate 
cycle to produce two CO2 molecules, three NADH and one FADH (flavin adenine 
dinucleotide in reduced form). The latter will transfer their electrons to the mito-
chondrial complexes of the electron respiratory chain; a series of redox transforma-
tion and the aid of molecular oxygen will finally converge in the synthesis of ATP by 
the ATP synthase complex.
Both ATP, NADH, and acetyl-CoA are metabolites that are shown to be ther-
modynamically favorable and are indicated as the protagonists in cellular energy 
metabolism [52].
After glycogen, the body stores energy in the form of TG in adipose tissue; 
nevertheless, diverse types of lipids are required for the maintenance of cellular 
functions, not only for energetic ones, but also structural (such as phospholipids) or 
for the formation of specialized products like steroid hormones. These are obtained 
from diet, absorbed and subsequently transported by lipoproteins such as the very 
high-density lipoprotein (VLDL), low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL), all of these ensembled by the liver. FFAs are a major source of 
acetyl-CoA molecules by β-oxidation, these molecules continue their oxidation in 
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the tricarboxylate cycle and the electron respiratory chain, providing a significant 
amount of energy at the cellular level.
Due to the importance of these biomolecules, there is a narrow regulation that 
includes transcription factors such as sterol regulatory element-binding proteins 
(SREBPs) and hormonal control for an adequate function [53].
Although these regulatory mechanisms are recognized, the possible regulatory 
activity that miRNAs may have in lipid and cholesterol homeostasis has recently 
been suggested, particularly for miR-122 and miR-33 [54].
3. Adipose tissue and disease
3.1 Insulin resistance
3.1.1 Obesity as a trigger
Obesity is a disease of multifactorial origin with a worldwide increasing 
prevalence; it entails an injurious health status for individuals, which represents a 
serious public health issue. This condition is associated to diverse diseases and has a 
complex treatment, being the reason why it must be assessed in a multidisciplinary 
context by healthcare professionals.
It is defined as an abnormal or excessive fat accumulation that can be detrimental 
for health [55]. It originates from the interrelation of inadequate food intake and/or 
overfeeding, sedentary lifestyle, and psychological, genetic, and ambiental factors. 
The excessive adiposity status hinders the disease reversion because of the difficulty 
to perform physical activity and the metabolic and satiety dysregulation [56].
Obesity develops a diversity of somatic complications such as respiratory, 
mechanic, cardiovascular, and metabolic, as well as psychological and social, which 
make its assessment, prognosis, and intervention even more complicated. Diagnosis 
is preceded by an anthropometric evaluation, which correlates adiposity with a total 
body weight of individuals [57].
Progressive AT expansion in the organism, given by a positive energy balance 
from excessive macronutrients and calorie intake, entails an elevated number 
of circulating FFA that triggers a deregulation in the organism, from changes 
in body structure to changes at local and systemic levels [58]. This excessive AT 
induces a chronic inflammatory state, also named lipoinflammation, causing 
hypoxia of adipocytes [59]. AT hypoxia and inflammation correlate with the risk 
of developing insulin resistance (IR), type 2 diabetes (T2D), and cardiovascular 
disease (CVD).
When the organism is under positive energy balance, energy excess accumulates 
in AT, giving place to SCAT hyperplasia until a physiologic allowed limit as energy 
reservoir is reached. When energy excess prevails, it is now stored at VAT; unfortu-
nately this depot does not possess a great capacity as SCAT, resulting in adipocyte 
hypertrophy and subsequent android, central, or visceral adiposity [60, 61].
Central obesity is highly associated with T2D and CVD. AT is the pathogenic 
site where obesity-induced local IR originates before being systemic; its secretory 
genetic expression profile of endocrine and paracrine bioactive substances reflects a 
generalized inflammatory local state, the reason why adipocyte is referred to as key 
to the onset and development of obesity-induced inflammation and to macrophages 
as amplifiers of this process [62].
As aforementioned, AT initially plays a role in energy reservoir but also has a 
significant function in metabolism and immune system. Resident ATMs are key in 
IR onset, as they produce proinflammatory molecules which can explain more than 
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50% of secretion of TNF-α, by the action of insulin on adipocytes and on peripheric 
organs of the body [63].
Other implicated adipokines are resistin and IL-6, which stimulate hormone-
sensitive lipase (HSL) activity resulting in triglycerides cleavage and subsequent 
glycerol and FFA release; these high circulating FFA levels are the cause and conse-
quence of IR and T2D [64].
We can broadly elucidate that adipocytes and ATMs synthesize proinflammatory 
molecules and that weight increase at the expense of AT will contribute in turn to 
the perpetuation of chronic inflammation by increasing the levels of circulating 
cytokines. Required actions to help reverse the IR process should be focused on 
establishing a healthy diet accompanied by exercise; these will help to reduce the 
proinflammatory state, while downregulation of TNF-α and IL-6 expression of 
adipocytes occur. Meanwhile, exercise by its own will enhance mitochondrial FFA 
metabolism, avoiding their storage [65].
Other factors involved in IR and inflammation are implicated by diet and related 
to gut microbiota, which in turn demonstrates how an excessive saturated fat con-
sumption can drive an important bacterial lipopolysaccharide (LPS) production, 
which impacts on systemic inflammation [58].
Initial steps that launch the inflammatory response are less well elucidated. On 
experimental studies with HFD-induced obesity murine models, HIF-1α levels are 
observed before the onset of a significant adiposity status; under this situation, 
adipocyte hypoxia and HIF-1α act as early triggers of inflammation and IR [59].
3.1.2 Inflammatory pathway
Adipose tissue complex and diverse functions have implications in the whole 
body, and cytokines are involved in his physiologic response. In obesity condition 
the major cytokines expressed by AT are leptin, resistin, TNFα, chemerin, MCP-1 
and IL-6 [66, 67]. On the other hand, the adipose cells are both hyperplastic and 
hypertrophic, and in this state induce the inflammatory process. Dysregulation 
of adipose tissue promotes incorrect remodeling and subsequent inflammation, 
according to recruitment of macrophages and expression of chemotactic cyto-
kines like MCP-1, TNFα and chemerin, to mention some of them. The phenotype 
involved is the M1 pro-inflammatory and evidence shows that this situation is not 
only local, but also systemic and this promotes further inflammation explaining 
how obesity can be the etiologic cause of other diseases [68, 69].
In addition, it is well known that this mechanism promotes insulin resistance, 
which is the previous phase before the development of T2D. However, the adipocyte 
is in a very close communication with the macrophage making the inflammatory 
process redundant and more complex. Nevertheless, in lean adipose tissue, it is 
typically the opposite, meaning that macrophages differentiate into a M2 anti-
inflammatory phenotype, releasing IL-10, TGFβ, IL-4, and other regulatory cyto-
kines [70]. Otherwise other mechanisms that can promote the anti-inflammatory 
pathway, like the consumption of Omega 3 fatty acids, exist [71].
Taking it all together, obesity results from genetic, epigenetic, physiological, 
behavioral, molecular and environmental factors that lead the proinflammatory 
phenotype [72, 73].
3.1.3 Molecular mechanism
It is described that adipose cells derive from a stem cell that can differentiate into 
adipocytes, chondrocytes, osteoblasts, and myocytes [74].
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In a first phase, adipoblasts can be addressed to the adipogenic lineage and 
become preadipocytes. If the stimuli in the tissue continue, these cells maturate to 
become mature adipose cells with lipid storage capacity [75].
There are two main transcription factors that are involved in the differentiation 
of the adipocyte, CCAAT/enhancer-binding protein α (C/EBP-α), and peroxisome 
proliferator-activated receptor γ (PPAR-γ). PPAR-γ is the most described tran-
scriptional factor, and its expression is regulated by the co-factor PGC1α and the 
production of adiponectin [76, 77].
Transcription factors that belong to the C/EBP family also have a crucial play 
in the differentiation, and there are reports that this factor can be activating more 
early than PPAR-γ (Figure 2) [78].
The dysfunction in the capacity of generating healthy adipose tissue has several 
metabolic consequences, like dyslipidemia, hypertension, and insulin resistance 
among others [79].
Many molecular mechanisms are involved since the adipocytes have different 
gene expression patterns, leading to the expression of different types of adipokines 
depending the phenotype induced in the tissue. Healthy expansion of adipocytes 
depends on the plasticity of the extracellular matrix, but in obesity there is a limit-
ing in the oxygen diffusion, and it becomes hypoxic [80].
3.1.4 Role of adipokines and myokines
Skeletal muscle compounds 40% of total body weight in healthy individuals. 
The muscle is the major site for the insulin-stimulated glucose uptake and lipid 
metabolism, so it is an important part of metabolism maintenance [81].
Adipose tissue possesses more than 600 potentially secretory proteins, which 
means that more adipokines and myokines are still in line for discovery and 
 characterization [82].
Additionally in adipokines there is a cross talk between these and myokines, 
which are synthetized by the muscle. Nevertheless, both tissues can express the 
same cytokines creating a regulation process with a strong communication. The 
most characterized cytokines are chemerin, TNFa, MCP-1 and IL-6. It is demon-
strated that WAT deposits exist in skeletal muscle and facilitate communication, 
also, these tissues usually are in close anatomical proximity.
Figure 2. 
Adipose tissue differentiation and hyperplasia and hypertrophy consequences.
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The knowledge of the most important characterized myokines is as follows:
IL-6: this increases in favor of the exercises, but it is recognized that it has a 
controversial role in the inflammatory or anti-inflammatory pathway.
Il-15: it mediates a beneficial effect on physical activity.
Irisin: it stimulates the development of brown adipose tissue activating MPK and 
ERK molecular ways, and it is regulated by the age and gender. This molecule has 
also a controversial role, because it has been reported to increase obesity.
Myonectin: it has a homology worth the sequence of adiponectin and promotes 
fatty acid uptaking in mice [82, 84–86].
Principally, the major role of the adipomyokines is contributing to metabolism, 
angiogenesis, blood vessel regulation, adipogenesis, myogenesis, and immune 
response [82]. On the other hand, it is important to remark the impact that mac-
rophages have in metabolism, since they induce a response in both tissues. For 
example, when circulating monocytes respond to chemoattractant molecules, they 
migrate into adipose and muscle tissue, and then develop a phenotype depending 
on environmental necessities (Table 1) [94].
Finally, there is another terminology newly adopted by the scientist called orga-
nokines, because it has been suggested that all proteins secreted in various tissues or 
organs (liver, adipose tissue, muscle, and bone) have an intimate relationship in the 
context of the communication and regulation for the maintaining of homeostasis 
and that they are involved in a network of paracrine and endocrine cross talk [84].
3.1.5 Emerging role of microRNAs in obesity
In the context of complex diseases, obesity is the prototype of immuno-
metabolic disease; it is considered a major factor that triggers metabolic risk and the 
development of secondary chronic illness2, insulin resistance (IR), and metabolic 
syndrome (MS). The susceptibility of a subject to develop obesity will depend on 
different factors such as the repertoire of individual variations in an ensemble of 
relevant genes, their history of exposure to environmental risk factors, and the 
interaction between the lifestyle and metabolism, which is also modulated by the 
gene regulators [95–97].
Meanwhile, obesity presents many subclinical manifestations, characterized by 
alterations in lipids and carbohydrate metabolism at different levels; most of these 
changes is due to a low-grade systemic chronic inflammation [98, 99] that favors the 
development of IR. Adipose tissue is the primary anatomical site where IR disease 
takes place; in early stage this tissue became inflamed.
IL-6 [87]
IL-8 [88]
MCP-1 [89]
Irisin [82]
PAI-1 [90]
PEDF [91]
FGF21 [92]
Fstl 1 [93]
Table 1. 
Best characterized adipomyokines.
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Novel findings on the immune-regulatory processes and metabolic mechanisms 
may open new avenues in the treatment of the common complex diseases as well as 
inflammatory component; research on basic and clinical advances in immunome-
tabolism has evolved rapidly during the past years, and the beginning of new tools 
for the detection and characterization of regulation of inflammation in metabolic 
diseases with comorbidity may play an imperative role; nevertheless, the precise 
mechanisms mediating this relationship remains poorly understood.
Interplay in the regulation of inflammation and metabolic risk factors are a com-
plex cluster. The inflammatory condition associated with adipose tissue represents a 
triggering factor in the etiology of the obesity pathological mechanisms and mainly 
contributes to the related disease outcomes.
In the early stages of obesity, in white adipose tissue, primed immune cells 
are recruited as adiposity increases, and these cells became resident cells (mainly 
macrophages) and secrete proinflammatory adipokines that promote further 
recruitment of circulating monocytes [100–103]. Later, they polarize toward M1 
macrophages, favoring a subclinical chronic inflammatory state [102, 104–106] 
secondary to irregular increase and distribution of fat depots [107]. In IR, the 
expression of genes implicated in glucose and lipid absorption and metabolism in 
liver and adipose tissue is dysregulated, at the same time, insulin signaling pathway 
in peripheral tissues is also disturbed [108]; this IR scenario precedes the develop-
ment of T2D and other related diseases.
The identification of diverse molecular mechanisms related to energy metabo-
lism has allowed the definition of strategies for searching genes implied in obesity 
and IR.
In the decade that precedes us, experimental reports show the existence of small 
noncoding RNAs, which are identified as microRNAs, (miRs) with the function of 
regulating cellular processes through modulating the expression of genes that code 
for functional proteins.
The insulin signaling pathways may be regulated by microRNAs (miRNA) that 
modulate the stability and translation of messenger RNAs (mRNA) by a particular 
mechanism of binding seeding sequences located in target genes, resulting in 
protein decay [109, 110].
Once synthesized, some miRNA can be released into circulation via exo-
somes, vesicular bodies, lipoproteins, simple extrusion, or apoptotic bodies. Most 
researches in the field have assessed the presence of circulating miRNA in many 
body fluids, being related to their impaired expression in tissues under physiological 
and pathological conditions. Several studies have shown a correlation of particular 
circulating miRNA with the development of different pathologies, positioning them 
as valuable biomarkers in silent diseases such as obesity, IR, and MS [111, 112].
Although rapid progress is being made in research on miRs, there is little avail-
ability of experimental tools with scientific value and mechanisms that lead from 
the discoveries of miRs to the therapeutic application in diseases. Therefore, the 
current demand is to explore the expression and biological function of miRs in the 
development of diseases in vivo.
The main considerations that are known are that the process of its biogenesis 
is governed by regulatory checkpoints, based on the fact that the sequence of the 
primary transcript does not correspond linearly to mature miR. The abundance or 
scarcity of a miR indicates its level of regulation.
Under physiological conditions, it has been shown that miRs modulate gene 
expression; however pathological stress increases or decreases its function. 
Therefore, its function will be defined by the effect on the expression of the genes 
to which it is directed. Predictions indicate that 60% of target mRNA genes have 
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similar binding sequences in the 3′UTR region for single or multiple miRs. These 
miRs exert their silencing function through two different mechanisms: transla-
tion inhibition (initiation or elongation) and target mRNA degradation. In the 
target genes for miRs, it is observed that 3′UTR regions have binding sites for 
multiple miRs; this suggests cooperation and redundancy of the effect on gene 
expression between the different miRs.
Currently, there are 1917 human miRNAs listed in the miRNA database miRBase 
(http://www.mirbase.org), representing 1% of all genes in the human genome. 
These miRNAs are predicted to target aprox. 30% of the human gene pool.
From the extraction of plasma and blood serum miRs from human and mam-
malian animal samples, they have been proposed as diagnostic biomarkers in the 
diseases. The attributes that stand out are that the miRs extracted from the serum 
have stability, and the results in the quantification are reproducible and consistent 
among individuals of the same species.
The logical sequence in the integral investigation of miRs is firstly to identify the 
presence in a given sample. The experimental tools used to measure the expression 
profile of miRs have been by microarray analysis or deep sequencing, while the 
determination of the level of expression of individual miRs has been performed by 
RT-PCR, in situ hybridization or northern blot.
However, the investigations carried out can be categorized from two conceptual 
points, the determination of the level of expression in which the most used meth-
odological tool is real-time PCR analysis and global expression assays. The former 
stand out for their specificity while confirming the latter, while the latter provide a 
broad view of the presence and regulation of miRs.
Properly identifying the functionality and level of expression of a specific miR 
is limited due to the high degree of sequence homology between some miRs and the 
size of the molecule; the parallel application of different molecular tools strength-
ens the identification or quantification process of the level of expression. However, 
an unfavorable factor is the combined regulation of multiple genes or small changes 
in gene regulation that are lost in biological noise.
Enhancing the work of performing research surrounding these novel gene 
regulators will advance our understanding of miRNAs and their specific func-
tions and will augment the opportunities to safely follow them as therapeutic 
targets [113].
3.2 IR in muscle and liver
Conventionally, insulin acts directly on the WAT under the cascade of the IRS1 
axis, PI3K, and AKT, for glucose absorption, with a possible positive feedback of the 
phosphorylation of Ser388 from IRS2, by cyclin-dependent kinase 4 (CDK4) [114], 
culminating with lipolysis regulation. However, as described in previous sections 
of the chapter, inflammatory processes and alternative activation of macrophages 
favor the pathogenic adiposity in which the action of insulin is not carried out cor-
rectly and therefore does not slow the lipolysis process.
Although the mechanism of signaling pathways that links pathogenic adiposity 
to insulin resistance in skeletal muscle and liver has not been well defined due to the 
difficulty of modeling in vitro systems that allow cell coordination as in a complex 
organism, the process of understanding molecular bases has lagged behind the 
direct action of insulin in an organ or cell. The best way to associate it is the chronic 
surplus of energy that favors the accumulation of ectopic lipids in the liver and 
skeletal muscle that trigger the activation of pathways that impair insulin signaling, 
causing the decrease in glucose absorption in muscle cells and of glycogenesis in 
liver [115].
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3.2.1 Liver
In a physiological stage with food withdrawal, the main source of glucose in the 
bloodstream is the liver. On the other hand, after absorption of nutrients by the 
intestine, the production of hepatic glucose should be interrupted in coordination 
with hyperinsulinemia.
The most assertive explanations of how insulin acts to promote glucose homeo-
stasis by inhibiting both glycogenolysis and hepatic gluconeogenesis have focused 
on the canonical pathway of insulin interacting directly in the liver by activating 
the insulin receptor (InsR) and the substrate of insulin receptor (IRS) and the 
phosphoinositol 3-kinase signaling cascade (PI3K/Akt/mTOR pathway) by inhibit-
ing transcription of the forkhead box class O-1FOXO1 factor and thus gene tran-
scription and activation of gluconeogenic enzymes such as phosphoenolpyruvate 
carboxykinase (PCK1) and glucose 6 phosphatase (G6PC) [116, 117].
However, it has been observed that suppression of hepatic glucose production 
is not totally dependent on the Akt activation pathway, for which remote insulin 
actions that interact indirectly with the physiological process of hepatic glucose 
have been studied. On one hand, the reduction of PCK1 and glucose 6-phosphatase 
(G6Pase) through cerebral insulin action activates the ATP-sensitive potassium 
channels (KATP) of hypothalamus and stimulate the vagal transmission and STAT3 
activation [118, 119], blocking the de novo glucose formation by the liver and there-
fore regulating serum hyperglycemia.
On the other hand, insulin action in WAT suppresses lipolysis and reduces the 
fatty acids flow into the liver, therefore, reduction of both acetyl-CoA concentra-
tion and pyruvate-to-glucose conversion occur, corresponding with the cessation 
of glycerol supply, observing a decrease in pyruvate carboxylase (PC) enzyme 
activity [120].
However, when WAT is in an inflammatory process and insulin resistance, it 
constantly increases the supply of gluconeogenic substrates, such as non-esterified 
fatty acids (NEFAS), and glycerol favors hepatic glucose production [121]. In stages 
with normal insulin levels, fatty acids in the bloodstream compete with glucose to 
internalize cells independent of hyperglycemia; however when insulin concentra-
tion or activity is deficient, fatty acids contribute directly to the production of 
glucose [122]. The ectopic accumulation of fatty acids in liver increases the content 
of acetyl-CoA allosterically activating PC and increasing gluconeogenesis; this 
increase in glucose and the presence of pro-inflammatory cytokines lead to inad-
equate insulin signaling in liver and subsequently, IR [123].
According to current knowledge of the importance of indirect insulin pathways 
in the liver to maintain the homeostatic glucose process, research groups will follow 
some therapeutic targets associated with the signaling pathways of G-protein-
coupled receptors (GPCRs) [124] as well as inhibitors of the enzyme acetyl-CoA 
carboxylase [125, 126] for the treatment of metabolic diseases. Similarly there 
is evidence that proves that the diet with low calorie concentrations can reverse 
hyperglycemia [127].
3.2.2 Muscle
The skeletal muscle is responsible for 70% of the elimination of total body glucose, 
associated with its capacity and energy need. Therefore, insulin sensitivity of skeletal 
muscle is critically important in maintaining homeostasis of blood glucose [128].
Many studies propose molecules related to the deterioration in insulin sig-
naling; however, they agree that these molecules accumulate when the energy 
supply exceeds the demand in the body. Therefore, it suggests that the IR in the 
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muscle not only has intrinsic problems as a reference. One of the main mecha-
nisms proposed to elucidate the pathogenic process of IR in skeletal muscle is 
mitochondrial compromise due to the bioenergetic imbalance present mainly in 
pathological adiposity. However, the molecular pathways to describe this event 
are not entirely elucidated.
In the physiological process of insulin/IR interaction in skeletal muscle, you can 
activate two signaling pathways with the phosphorylation of IRS1 and, on the one 
hand, the PI3K/AKT pathway that induces glycogen synthesis and glucose uptake 
by recruiting the transporter protein of glucose (GLUT-4) to the plasma membrane, 
while the activation of the MAPK pathway favors the growth and differentiation of 
skeletal muscle [129].
The presence of pathological adiposity provides high concentrations of fatty 
acids and cytokines that activate signaling pathways linked to obesity that con-
verge with insulin signaling. As plasma FFA increase, they accumulate in muscle. 
Intramuscular diacylglycerol (DAG) and ceramides levels rise, compounds that 
might act as second messengers in alternative signaling pathways that interfere with 
IRS-1 adequate phosphorylation [108, 130].
The presence of TAG and DG in muscle activates Ser307 phosphorylation in IRS-
1, resulting in the activation of PKC-θ. These changes in turn result in a decrease in 
the tyrosine phosphorylation of IRS-1 and a lower activation of the PI3K associated 
with IRS-1, resulting in a decrease in insulin-stimulated glucose transport activity. 
Intramolecular lipids (IMCL) have been observed to be elevated when lipid oxida-
tion is poor and lipid supply to the muscle is exceeded [120, 131, 132].
The bioenergetic imbalance favors mitochondrial beta oxidation, although 
incompletely which can increase the concentration of reactive oxygen species (ROS) 
mainly H2O2, this reactive species is responsible for the inhibition of PP2A causing 
the activation of JNK and ERK, and these inhibit serine phosphorylation in IRS1. 
When the energy demand is exceeded, skeletal muscle mitochondria stimulate lipid 
biosynthesis that redundantly increases the concentration of ROS and myocellular 
lipids [133–135].
Although the process by which ROS and fatty acids trigger insulin resistance is 
not yet elucidated, it can be deduced that energy imbalance is the fundamental key.
4. A new terminology: pathologic adiposity
Total adipose mass, fat depot location, and particular AT type function are the 
predominant factors that explain high metabolic risk in individuals with obesity, 
since number, distribution, and leucocyte population differ between SCAT and 
VAT from lean and obese individuals; VAT has higher a macrophage number, and 
adipocyte size is smaller and has less lipid storage capacity. These differences 
suggest VAT can undergo subclinical inflammation and metabolic disease [136]; 
actually, central obesity associates with higher CVD, metabolic disorders, and early 
death, in contrast with gynecoid obesity at the expense of SCAT accumulation in 
the gluteofemoral region [13].
With the aforementioned, we can state that not every obese individual 
is affected by the common metabolic abnormalities associated with obesity. 
Approximately 10–25% of obese and a smaller fraction of morbidly obese persons 
are “metabolically healthy” (metabolically healthy obese, MHO), as they are insulin 
sensitive and normotensive and possess a favorable lipid profile; furthermore, they 
present less VAT and hepatic lipids and possess normal glucose metabolism. On the 
other hand, a subgroup of normal weight individuals suffers obesity characteristic 
metabolic abnormalities, whereby they are denominated as “metabolically healthy 
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but with normal weight” (MONW). It is suggested that MHO individuals own a 
less detrimental metabolic profile and better prognosis compared to normal weight 
individuals with metabolic syndrome [137–139].
As stated before in this chapter, under acute caloric excess, enlarged adipocytes 
suffer hypoperfusion and mechanic stress owing to its surrounding ECM, which 
causes transient hypoxia and triggers angiogenesis and release of stress signals so 
that AT could undergo healthy remodeling and maintenance [140].
Nonetheless, obesity is a chronic caloric excess state, which means adipocyte 
enlargement surpasses angiogenesis, whereby hypoxia and stress signals perpetuate 
and cause fibrosis and cell death with eventual necrosis; this scenario causes local 
lipotoxicity, as ATM lipid buffering function is surpassed by the increased FFAs lev-
els caused by overfeeding or adipocyte lipolysis and death [141, 142]. Thus, ATMs 
undergo metabolic activation, as lipids like palmitate are TLR-2/4 ligands, therefore 
initiating a proinflammatory response and polarization towards a M1 phenotype, 
losing all pro-homeostatic functions that we have previously discussed [143–145]. 
Figure 3. 
A series of unfortunate events that leads to a pathologic adiposity status.
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Furthermore, the other resident leucocytes will change in number and function as 
ATMs did, towards a Th1-type immune response.
The activation of NF-kB pathway with cytokine/chemokine release and the con-
tribution of harmful metabolites (i.e., ceramide and sphingosine 1-phosphate, S1P) 
interfere with proper insulin signaling, therefore establishing a local AT IR [146–148].
After the AT IR is established, non-suppressive lipolysis now perpetuates and 
triggers high circulating FFA levels giving place to peripheral/systemic lipotoxicity: 
ectopic fat accumulation in liver and muscle; additionally, the proinflammatory 
cytokine, adipokine, and chemokine profile will circulate through the bloodstream, 
establishing metainflammation. Eventually, the high ectopic lipid concentration in 
this tissues will unleash similar detrimental effects that took place at AT, establish-
ing now peripheral/systemic IR and dyslipidemia [132, 149].
The ensemble of this AT dysfunction and its harmful metabolic clinical reper-
cussions is what we call pathologic adiposity: the adiposity status that determinates 
metabolic systemic dysfunction (IR and dyslipidemia), whether in an obese or 
normal weight individual, “metabolically unhealthy obese” (MUO), or “metaboli-
cally obese normal weight” (MONW) person, respectively (Figure 3).
5. Conclusions
Metainflammation can be defined as the systemic metabolic inflammation 
derived from obese adipose tissue in which innate and adaptive immune system 
cells have changed in number and function, from a lean and homeostatic to a pro-
inflammatory state, and whose cytokine and adipokine proinflammatory profiles 
cause metabolic syndrome. Some authors consider metainflammation as the result 
of dysfunctional adipose tissue that consists of unhealthy expansion (hypertrophy) 
and angiogenesis, hypoxia, and detrimental ECM remodeling, which in turn limit 
adipocyte lipid storage capacity; altogether, these deleterious scenarios cause 
lipolysis and ectopic fat accumulation in the liver and muscle.
The knowledge developed in recent years in relation to the homeostatic interac-
tion between immune system and the energetic metabolism along with the role of 
miRs allows that in a state in imbalance such as obesity, new biomarkers that show 
clinical information about the state are sought health of individuals and the early 
detection of the risk of developing metabolic complications is derived from the state 
of pathological adiposity.
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Acronyms and abbreviations
ADRB3 β3-adrenergic receptor
AKT protein kinase B
ASCs adipose stem cells
AT adipose tissue
ATMs adipose tissue macrophages
ATP adenosine triphosphate
BAT brown adipose tissue
C/EBP-α CCAAT/enhancer-binding protein α
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CDK4 cyclin-dependent kinase 4
CDS critical death size
CVD cardiovascular disease
DWAT dermal WAT
ECM extracellular matrix
ERK extracellular signal-regulated kinase-1
FADH flavin adenine dinucleotide in reduced form
FFA free fatty acids
FGF21 fibroblast growth factor 21
FOXO1 forkhead box class O-1
Fstl 1 follistatin-related protein 1
G6PaseC glucose 6 phosphatase
GLUT transporter protein of glucose
HDL high-density lipoproteins
HFD high-fat diet
HIF-1α hypoxia-inducible factor-1α
HSL hormone sensitive lipase
IL interleukin
ILC2 group 2 innate lymphoid cells
IMCL intramolecular lipids
iNKT invariant natural killer T cells
IR insulin resistance
IRS1 substrate of insulin receptor 1
IRS2 substrate of insulin receptor 2
KATP ATP-sensitive potassium channels
LDL low-density lipoprotein
LPS lipopolysaccharide
MCP-1 monocyte chemoattractant protein-1
miRs microRNAs
MPK mitogen-activated protein kinase
mRNA messenger RNAs
MS metabolic syndrome
MSCs mesenchymal stem cells
NADH nicotinamide adenine dinucleotide in reduced form
NEFAS non-esterified fatty acids
OPN osteopontin
PAI-1 plasminogen activator inhibitor-1
PCK1 phosphoenolpyruvate carboxy kinase
PC pyruvate carboxylase
PDGF platelet-derived growth factor
PDGFR platelet-derived growth factor receptor
PEDF pigment epithelium-derived factor
PI3K phosphoinositide 3-kinases
PPAR-γ peroxisome proliferator-activated receptor γ
RT-PCR real-time polymerase chain reaction
SCAT subcutaneous adipose tissue
SIRT 1 sirtuin 1
SPARC secreted protein, acidic, and rich in cysteine complex
SREBPs sterol regulatory element-binding proteins
STAT3 signal transducer and activator of transcription 3
SVF stromal-vascular fraction
S1P sphingosine-1-phosphate
TZD thiazolidinediones
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Treg regulatory T lymphocytes
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VLDL very-low-density lipoprotein
WAT white adipose tissue
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